Sequencing of agents in castration-resistant prostate cancer.
about
Galeterone for the treatment of advanced prostate cancer: the evidence to dateRadium-223 and metastatic castration-resistant prostate cancer: All that glitters is not goldFirst-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Activation of AMPKα mediates additive effects of solamargine and metformin on suppressing MUC1 expression in castration-resistant prostate cancer cellsTargeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.Drug discovery in advanced prostate cancer: translating biology into therapy.Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer.Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.The evolution of chemotherapy for the treatment of prostate cancer.Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters.The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A.Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.Targeted and Nontargeted α-Particle Therapies.Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.Treating breast cancer metastasis with cabazitaxel-loaded polymeric micelles.Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems.Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective RegistryCollateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants
P2860
Q26739887-FAD343CE-77B7-4D11-B456-249F0D36D520Q28066293-C6686232-4E3B-48F4-8D62-91C19B830A54Q36243639-F9709DDC-960B-433A-9FFD-877FA8D6A473Q36407003-BBB1A05D-D4EF-4C99-B77F-BBF13F880E73Q37405631-118CB80B-2D6F-457A-A6C2-C6EA8BF362B1Q37496652-BFED3243-0446-47B4-8DC2-DBD222D3EE6EQ37531813-4D8D06AF-BE95-4016-9ADF-69620C5FAC98Q37709535-C1E4ACD0-477B-49FF-9D79-D29E4BFBE3F8Q38644658-A2DA0217-9D76-4C97-8F49-D74D7984BA98Q38804089-6D28142B-80EE-4430-878C-88198B5C916FQ38813222-0A27FACF-094B-47BE-BBCF-C20622481C82Q38839110-7FF7F005-015C-427E-B6FF-AE74A019C411Q38852008-43EAECAC-DFCA-4530-86F8-4EFB4F86971CQ38983833-EEFE2762-E1BD-4592-BF78-8E0D3BC105D4Q39487974-D9640096-9A44-4438-9403-DC254D29B1EAQ40608123-20F43BBA-AEB0-46A1-BA54-341BE0AA8285Q40830449-2BC2F089-F123-4B23-BB1C-E1FBC7C63C47Q41332423-BC8ABBD9-DF6E-4815-A819-2BE967345E2EQ42908773-09D28193-EB6D-43C3-B473-B3A9DA98FA86Q45943517-AB30F2D6-41BE-4E7D-86DE-B3BE6CE20C77Q46855168-DB96397F-B774-42CF-B93A-4F8C6B78EB45Q47138098-93DD70E5-2957-47E0-BCAB-3F3DF0C93827Q47563547-D8B6495E-C4C1-42C5-9E98-3358344EF4B2Q47685684-26F994DE-1D95-4F3E-AE02-3F46F51AFDECQ48254532-52152166-8942-41BF-AA2E-F6786F9E9A72Q48370675-8F02508C-7A45-4125-A909-708165FA78D2Q49967540-7A716669-A67A-4D19-95BA-9BE1AFB821F2Q50184896-B8199467-001E-4EE1-B6B2-88BCEE3833F1Q50642716-33BDC99E-A27F-494D-B5FB-8977EDB3018AQ52676556-9BF56F58-0F62-48D8-A7D2-90AABB35FBC8Q52852575-37D55E0C-9BF2-45F6-99D3-AA5BD3C48623Q55285232-4EC460ED-48BB-464A-BF28-861059F246BDQ58692138-D3BEC540-F462-4CB6-B579-395B812B4D03Q58697074-577A9AC3-92C3-451B-8477-99E60744C034
P2860
Sequencing of agents in castration-resistant prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Sequencing of agents in castration-resistant prostate cancer.
@en
type
label
Sequencing of agents in castration-resistant prostate cancer.
@en
prefLabel
Sequencing of agents in castration-resistant prostate cancer.
@en
P2093
P1433
P1476
Sequencing of agents in castration-resistant prostate cancer.
@en
P2093
David Lorente
Joaquin Mateo
Johann S de Bono
Raquel Perez-Lopez
P304
P356
10.1016/S1470-2045(15)70033-1
P577
2015-05-27T00:00:00Z